- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- homo-tetramer
- Ligands
- 36 x POV: (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate(Non-covalent)
- 4 x 8IJ: (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctadecanoate(Non-covalent)
8IJ.2: 36 residues within 4Å:- Chain A: H.413, D.511, S.512, Y.513, S.514, M.516, L.517, F.518, L.520, F.524, F.545, A.548, L.549, T.552, N.553, L.555, Y.556, R.559, I.571, E.572, K.573, I.575, L.576, I.699, L.702, Q.703, I.706
- Chain B: F.589, F.593, I.664, L.665, A.668, L.672
- Ligands: POV.1, POV.8, POV.13
28 PLIP interactions:25 interactions with chain A, 3 interactions with chain B- Hydrophobic interactions: A:Y.513, A:M.516, A:L.517, A:L.517, A:L.520, A:F.524, A:F.545, A:F.545, A:A.548, A:L.549, A:L.555, A:L.555, A:Y.556, A:I.575, A:I.575, B:F.593, B:I.664, B:A.668
- Hydrogen bonds: A:D.511, A:D.511, A:Y.513, A:S.514, A:E.572, A:E.572, A:K.573, A:Q.703
- Salt bridges: A:R.559, A:R.559
8IJ.17: 36 residues within 4Å:- Chain B: H.413, D.511, S.512, Y.513, S.514, M.516, L.517, F.518, L.520, F.524, F.545, A.548, L.549, T.552, N.553, L.555, Y.556, R.559, I.571, E.572, K.573, I.575, L.576, I.699, L.702, Q.703, I.706
- Chain C: F.589, F.593, I.664, L.665, A.668, L.672
- Ligands: POV.15, POV.16, POV.24
27 PLIP interactions:25 interactions with chain B, 2 interactions with chain C- Hydrophobic interactions: B:Y.513, B:M.516, B:L.517, B:L.517, B:L.520, B:F.524, B:F.545, B:F.545, B:A.548, B:L.549, B:L.555, B:L.555, B:Y.556, B:I.575, B:I.575, C:F.593, C:I.664
- Hydrogen bonds: B:D.511, B:D.511, B:Y.513, B:S.514, B:E.572, B:E.572, B:K.573, B:Q.703
- Salt bridges: B:R.559, B:R.559
8IJ.27: 36 residues within 4Å:- Chain C: H.413, D.511, S.512, Y.513, S.514, M.516, L.517, F.518, L.520, F.524, F.545, A.548, L.549, T.552, N.553, L.555, Y.556, R.559, I.571, E.572, K.573, I.575, L.576, I.699, L.702, Q.703, I.706
- Chain D: F.589, F.593, I.664, L.665, A.668, L.672
- Ligands: POV.25, POV.26, POV.34
28 PLIP interactions:25 interactions with chain C, 3 interactions with chain D- Hydrophobic interactions: C:Y.513, C:M.516, C:L.517, C:L.517, C:L.520, C:F.524, C:F.545, C:F.545, C:A.548, C:L.549, C:L.555, C:L.555, C:Y.556, C:I.575, C:I.575, D:F.593, D:I.664, D:A.668
- Hydrogen bonds: C:D.511, C:D.511, C:Y.513, C:S.514, C:E.572, C:E.572, C:K.573, C:Q.703
- Salt bridges: C:R.559, C:R.559
8IJ.36: 36 residues within 4Å:- Chain A: F.589, F.593, I.664, L.665, A.668, L.672
- Chain D: H.413, D.511, S.512, Y.513, S.514, M.516, L.517, F.518, L.520, F.524, F.545, A.548, L.549, T.552, N.553, L.555, Y.556, R.559, I.571, E.572, K.573, I.575, L.576, I.699, L.702, Q.703, I.706
- Ligands: POV.9, POV.35, POV.42
28 PLIP interactions:25 interactions with chain D, 3 interactions with chain A- Hydrophobic interactions: D:Y.513, D:M.516, D:L.517, D:L.517, D:L.520, D:F.524, D:F.545, D:F.545, D:A.548, D:L.549, D:L.555, D:L.555, D:Y.556, D:I.575, D:I.575, A:F.593, A:I.664, A:A.668
- Hydrogen bonds: D:D.511, D:D.511, D:Y.513, D:S.514, D:E.572, D:E.572, D:K.573, D:Q.703
- Salt bridges: D:R.559, D:R.559
- 2 x NA: SODIUM ION(Non-functional Binders)
NA.11: 5 residues within 4Å:- Chain A: G.646
- Chain B: G.646
- Chain C: G.646
- Chain D: G.646
- Ligands: NA.12
1 PLIP interactions:1 interactions with chain C- Hydrogen bonds: C:G.646
NA.12: 5 residues within 4Å:- Chain A: G.646
- Chain B: G.646
- Chain C: G.646
- Chain D: G.646
- Ligands: NA.11
No protein-ligand interaction detected (PLIP)- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Neuberger, A. et al., Human TRPV1 structure and inhibition by the analgesic SB-366791. Nat Commun (2023)
- Release Date
- 2023-05-10
- Peptides
- Transient receptor potential cation channel subfamily V member 1: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- homo-tetramer
- Ligands
- 36 x POV: (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate(Non-covalent)
- 4 x 8IJ: (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctadecanoate(Non-covalent)
- 2 x NA: SODIUM ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Neuberger, A. et al., Human TRPV1 structure and inhibition by the analgesic SB-366791. Nat Commun (2023)
- Release Date
- 2023-05-10
- Peptides
- Transient receptor potential cation channel subfamily V member 1: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
D - Membrane
-
We predict this structure to be a membrane protein.